Expression of steroid receptor coactivators in cultured cells from paired myometrial and fibroid tissues.
OBJECTIVE
Fibroid tumor growth in the myometrium appears to be regulated by estrogens but the role of estrogen receptor (ER) coregulators, such as the steroid receptor coactivator (SRC) family members, in fibroid growth is currently unknown. The aims of this study were to compare the expression of the SRC-1, SRC-2, and SRC-3 coactivators between fibroids and normal myometrium in pure populations of cultured smooth muscle cells (SMC) and microvascular endothelial cells (MEC), and also between both cell types, and to identify any relationship between the SRC expression profiles and the known ER status of the SMC and MEC samples examined in this study.


METHODS
Reverse transcriptase-polymerase chain reaction (RT-PCR) coupled with Southern blot analysis was used to derive a semiquantitative estimate of the relative levels of SRC-1, SRC-2, and SRC-3 expression in pure populations of SMC (>98% alpha-smooth muscle actin [SMA](+)) and MEC (>99% CD31(+)) isolated and cultured from eight samples of paired human myometrial and fibroid tissue.


RESULTS
The mean levels of SRC-1, SRC-2, and SRC-3 were each similar in normal myometrium compared to fibroids for SMC and also for MEC. However, SRC-1, SRC-2, and SRC-3 levels were each significantly higher in SMC compared to MEC from both myometrial and fibroid samples, although for SRC-3 there was a trend for higher levels in myometrial samples that did not reach significance. While all SMC samples expressed ERalpha and high coactivator levels, there does not appear to be a relationship between coactivator expression levels and the presence or absence of ERalpha in MEC samples.


CONCLUSIONS
Coactivators may be more important in ERalpha-mediated growth of SMC than for MEC. Although the SRC family members are likely to play a role in the response of fibroid SMC to estrogen, via ERalpha, changes in their levels do not appear to contribute to the increased sensitivity of fibroid SMC to estrogen.
Prince Henry's Institute of Medical Research and Monash University Department of MedicineClayton, Victoria, Australia.
Sonay
S
Hussein-Fikret
Peter J
PJ
Fuller
Caroline E
CE
Gargett
D000123:Acetyltransferases / Q000096:biosynthesis*; D000328:Adult; D015139:Blotting, Southern; D047628:Estrogen Receptor alpha / Q000502:physiology*; D005260:Female; D020869:Gene Expression Profiling; D051548:Histone Acetyltransferases; D006801:Humans; D007889:Leiomyoma / Q000235:genetics* / Q000473:pathology; D008875:Middle Aged; D009130:Muscle, Smooth / Q000166:cytology / Q000502:physiology; D009215:Myometrium / Q000502:physiology; D056920:Nuclear Receptor Coactivator 1; D051958:Nuclear Receptor Coactivator 2 / Q000096:biosynthesis*; D056921:Nuclear Receptor Coactivator 3; D015513:Oncogene Proteins / Q000096:biosynthesis*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D015534:Trans-Activators / Q000096:biosynthesis*; D014157:Transcription Factors / Q000096:biosynthesis*; D014407:Tumor Cells, Cultured; D014594:Uterine Neoplasms / Q000235:genetics* / Q000473:pathology
D047628:Estrogen Receptor alpha; D051958:Nuclear Receptor Coactivator 2; D015513:Oncogene Proteins; D015534:Trans-Activators; D014157:Transcription Factors; D000123:Acetyltransferases; D051548:Histone Acetyltransferases; C538859:NCOA1 protein, human; C538866:NCOA3 protein, human; D056920:Nuclear Receptor Coactivator 1; D056921:Nuclear Receptor Coactivator 3